Zobrazeno 1 - 10
of 25
pro vyhledávání: '"A M, Kusske"'
Autor:
Deanna J. Attai, Farnaz Haji, Anne C. Hoyt, Maggie L DiNome, Cheryce P. Fischer, Carlie K Thompson, Jennifer L. Baker, Amy M. Kusske, Minna K Lee
Publikováno v:
Breast Cancer Research and Treatment. 191:107-114
In clinically node-positive breast cancer, axillary staging after neoadjuvant chemotherapy (NAC) is optimized with targeted axillary dissection (TAD), which includes removal of the biopsy-proven metastatic lymph node (LN) in addition to sentinel lymp
Autor:
Carlie K Thompson, Minna K Lee, Maggie L. DiNome, Jennifer L. Baker, Yas Sanaiha, Cheryce P. Fischer, Amy M. Kusske, Deanna J. Attai
Publikováno v:
Breast Cancer Research and Treatment. 182:299-303
Multiple wire-free technologies for localization of non-palpable breast cancers have emerged as satisfactory alternatives to wire. However, no study has compared two non-radioactive wire-free approaches to one another. The purpose of this study was t
Autor:
Jennifer L, Baker, Farnaz, Haji, Amy M, Kusske, Cheryce P, Fischer, Anne C, Hoyt, Carlie K, Thompson, Minna K, Lee, Deanna, Attai, Maggie L, DiNome
Publikováno v:
Breast cancer research and treatment. 191(1)
In clinically node-positive breast cancer, axillary staging after neoadjuvant chemotherapy (NAC) is optimized with targeted axillary dissection (TAD), which includes removal of the biopsy-proven metastatic lymph node (LN) in addition to sentinel lymp
Autor:
Anne C. Hoyt, Joanne B. Weidhaas, Xiaoyan Wang, Susan A. McCloskey, John V. Hegde, Michael L. Steinberg, Maggie L. DiNome, Deanna J. Attai, Sara A. Hurvitz, Amy M. Kusske
Publikováno v:
Breast Cancer Research and Treatment. 166:145-156
For women with a personal history of breast cancer (PHBC), no validated mechanisms exist to calculate future contralateral breast cancer (CBC) risk. The Manchester risk stratification guidelines were developed to evaluate CBC risk in women with a PHB
Publikováno v:
Breast cancer research and treatment. 175(1)
Use of a wire to localize a non-palpable breast lesion for surgery is standard but archaic. We sought to evaluate a new radiofrequency localization system (RFLS) as an effective, non-radioactive alternative to the wire. Patients who required surgical
Autor:
Michael L. Steinberg, Susan A. McCloskey, Amy M. Kusske, Maggie L. DiNome, John V. Hegde, Anne C. Hoyt, Joanne B. Weidhaas, Sara A. Hurvitz, Xiaoyan Wang, Deanna J. Attai
Publikováno v:
Clinical breast cancer. 18(2)
Contralateral prophylactic mastectomy (CPM) rates are rising, with fear implicated as a contributing factor. This study used a contralateral breast cancer (CBC) risk stratification tool to assess whether the selection of CPM is reflective of future C
Autor:
Robyn Lynn Dvorak, Nicole A. Dawson, Nova Foster, Susan A. McCloskey, Amar U. Kishan, C.L. Gomez, Sara A. Hurvitz, Amy M. Kusske, Erica L. Silver, Anne C. Hoyt, Charles C. Tseng
Publikováno v:
Annals of surgical oncology. 23(Suppl 5)
Findings show that 5-10 % of women with a diagnosis of breast cancer (BCa) have actionable genetic mutations. The National Comprehensive Cancer Network guidelines for testing to detect BRCA1/2 mutations include personal history (PH) variables such as
Autor:
Susan A. McCloskey, Amy M. Kusske, Sara A. Hurvitz, John V. Hegde, Anne C. Hoyt, M.L. DiNome, Xiaoyan Wang
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 99:E17-E18
Publikováno v:
Cancer Research. 77:P3-02
Purpose Women with a personal history of breast cancer (BC), in the absence of genetic predisposition or significant family history, are generally categorized as having an intermediate (15-20%) risk of developing future BC. Screening MRI is recommend
Autor:
David W. McFadden, Anthony J. Rongione, Todd R. Newton, Amy M. Kusske, Stanley W. Ashley, Michael J. Zinner
Publikováno v:
Digestive Diseases and Sciences. 46:1740-1747
Growth factor-stimulated intestinal absorption has recently been described, but the cellular transport mechanisms mediating this response are unknown. The purposes of this study were to examine the effect that intraluminal and systemic EGF and TGF ha